Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
barda [2022/12/19 20:45] pamela [BARDA 2022-2026 Strategic Plan] | — (current) | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ===== BARDA - Biomedical Advanced Research and Development Authority ===== | ||
- | {{ :: | ||
- | The Biomedical Advanced Research and Development Authority is a U.S. Department of [[:Health and Human Services]] office responsible for the procurement and development of medical countermeasures created in 2006. Together with its industry partners, BARDA promotes the advanced development of medical countermeasures. | ||
- | |||
- | The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, | ||
- | |||
- | Together with its industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats.((https:// | ||
- | |||
- | ==== BARDA Director ==== | ||
- | Director, Biomedical Advanced Research and Development Authority | ||
- | Deputy Assistant Secretary for Preparedness and Response | ||
- | U.S. Department of Health and Human Services | ||
- | |||
- | Dr. [[:Gary Disbrow]] is the Director of the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.((https:// | ||
- | |||
- | |||
- | {{:: | ||
- | |||
- | |||
- | ==== BARDA’s Expanding COVID-19 Medical Countermeasure Portfolio ==== | ||
- | |||
- | BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust [[: | ||
- | |||
- | |||
- | This page is updated regularly, but may not include all awards | ||
- | |||
- | All (98) Vaccines (7) Diagnostics (55) Therapeutics (16) Rapidly Deployable Capabilities (15) Other (5) | ||
- | {{ :: | ||
- | |||
- | * [[:Pfizer]] Inc. | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * BD ([[:Becton Dickinson]] and Company) | ||
- | * BD COR System Respiratory Panel | ||
- | * | ||
- | * Learn More | ||
- | * BD ([[:Becton Dickinson]] and Company) | ||
- | * BD MAX System Respiratory Panel plus Pan-Coronavirus | ||
- | * | ||
- | * Learn More | ||
- | * BD ([[:Becton Dickinson]] and Company) | ||
- | * BD COR System Respiratory Panel plus Pan-Coronavirus | ||
- | * | ||
- | * Learn More | ||
- | * BD ([[:Becton Dickinson]] and Company) | ||
- | * BD Veritor Plus System Respiratory Panel | ||
- | * | ||
- | * Learn More | ||
- | * BD ([[:Becton Dickinson]] and Company) | ||
- | * BD MAX System Respiratory Panel | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * Xpert Xpress SARS-CoV-2/ | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * Xpert Pan-Coronavirus test panel | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Xpert Xpress SARS-CoV-2 test | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * eCART | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * ADVIA Centaur® [[: | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * Ortho Clinical Diagnostics | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Ortho Clinical Diagnostics | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * Visby Medical Flu & COVID-19 test | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * DPP® Respiratory Panel Antigen Test System | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * DPP® SARS-CoV-2 Antigen | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * Mesa Biotech, Inc. | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * ** Single-Administration Microneedle Skin Patch for Pandemic Vaccine** | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Aura | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Point of Care SARS-CoV-2 Sofia 2 Antigen Assay | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 2 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Rapid Sepsis Diagnostic | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 3 | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * Vela Diagnostics USA, Inc. | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * ePlex Respiratory Pathogen v2 Panel | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * EUA Issued | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Rapid SARS-CoV-2 Antibody Test for HemBox™ Biosensor System | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * Rapid SARS-CoV-2 Antigen Test for HemBox™ Biosensor System | ||
- | * | ||
- | * Learn More | ||
- | * | ||
- | * | ||
- | * Phase 2/3 | ||
- | * Learn More ((https:// | ||
- | |||
- | |||
- | ==== BARDA 2022-2026 Strategic Plan ==== | ||
- | {{ :: | ||
- | STATEMENT FROM THE BARDA DIRECTOR, [[:GARY DISBROW]], PhD | ||
- | {{:: | ||
- | On the release of BARDA' | ||
- | |||
- | Full Plan((https:// | ||
- | |||
- | |||
- | |||